MedAssets Appointed by CTCA

Zacks

MedAssets, Inc. (MDAS), a company dedicated to revenue cycle management and supply chain management, recently revealed that the Cancer Treatment Centers of America (:CTCA) had appointed it to derive lower costs for new projects under construction across its nation-wide chain of hospitals. This fresh understanding to utilize MedAssets Capital and Construction Solutions builds upon the existing arrangements between the two sides in such areas as Reimbursement and Charge Integrity.

MedAssets furnishes a tech-friendly offering that provides a mechanism for comparison and purchase of construction-related products. Furthermore, by centralizing purchase decisions, and utilizing both analysis and intelligence in its decision making, MedAssets intends to deliver both financial and operational benefits to CTCA. In other words, MedAssets’ clients benefit across a range of parameters, including cost savings. 

Every cancer hospital of CTCA makes use of up-to-date technology and trained staff. Due to the rising demand for new services, CTCA needs to add new facilities at its hospitals. By appointing MedAssets, CTCA benefits from a cloud-based offering that allows financial control of projects from start to conclusion. 

Cancer Treatment Centers of America (:CTCA) is a chain of hospitals that provide care for cancer patients. Through programs such as Patient Empowerment Medicine, it disseminates data about cancer such that cancer victims may take control over their medication.

MedAssets teams with health-related entities to implement revenue cycle management and other offerings that curb costs and lead to better margins and cash flow. The company works with over 4,200 hospitals and 122,000 health providers.

We currently have a Zacks Rank #3 (Hold) on MedAssets. We are more positive about Air Methods Corp. (AIRM), Express Scripts Holding Company (ESRX) and Healthways Inc. (HWAY) each of which carry a Zacks Rank #2 (Buy) and are expected to do well.  

Read the Full Research Report on MDAS

Read the Full Research Report on HWAY

Read the Full Research Report on ESRX

Read the Full Research Report on AIRM

Zacks Investment Research



More From Zacks.com
View Comments (0)